TICKERNERD
Menu
KNSAKNSAHealthcare · Drug Manufacturers - Specialty & Generic

KNSA Stock Forecast: Kiniksa Pharmaceuticals International Plc Price Predictions for 2026-2027

Last close, 11 Sept 2026
$76
−0.27% on the day

The 8 Wall Street analysts covering Kiniksa Pharmaceuticals International Plc hold a median 12-month price target of $99 — +29.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 98 of 100 as at 12 Sept 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$6.0B
Ticker Nerd rank
98 / 100
Median analyst target
$99
Analysts covering
8
Revenue$243.6M+55.4% y/y
Operating income$27.2M
Net income$25.4M
Free cash flow$46.5M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−5.2%
1M
−2.0%
YTD
+84.9%
1Y
+106.1%
From 52W high
−5.7%
From 52W low
+115.3%
$35
$81
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

KNSA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Kiniksa Pharmaceuticals International Plc on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
98 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
97
Momentum
97
Value
96
Quality
90
Growth
89
Accruals
77
Revisions
71
Issuance
50
Size
21

Volatility (97): The share price has been relatively steady.

Issuance (50): The company has been issuing shares or taking on financing, diluting existing holders.

Size (21): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

KNSA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on KNSA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$40$60$80$100$120Oct 25Jan 26Apr 26Jul 26KNSAHigh $108Median $99Low $87

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says8 analysts
8 Buy0 Hold0 Sell
Low $87Median $99High $108

The green dot is the last close — the median target sits +29.1% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 7 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
30 July 2026Goldman SachsMaintainsBuy$75 → $90
29 July 2026Canaccord GenuityMaintainsBuy$64 → $98
29 July 2026CitigroupMaintainsBuy$60 → $100
29 July 2026JP MorganMaintainsOverweight$72 → $107
29 July 2026WedbushMaintainsOutperform$72 → $99
23 July 2026Goldman SachsMaintainsBuy$60 → $75
13 July 2026Wells FargoMaintainsOverweight—
13 July 2026Wells FargoMaintainsOverweight$57 → $74
29 June 2026WedbushMaintainsOutperform—
29 Apr 2026Canaccord GenuityMaintainsBuy—
29 Apr 2026CitigroupMaintainsBuy—
29 Apr 2026WedbushMaintainsOutperform—
29 Apr 2026Wells FargoMaintainsOverweight—
28 Apr 2026JefferiesMaintainsBuy—
16 Apr 2026WedbushMaintainsOutperform—
25 Feb 2026WedbushMaintainsOutperform—
25 Feb 2026Wells FargoMaintainsOverweight—
19 Feb 2026Canaccord GenuityInitiatesBuy—
13 Jan 2026WedbushMaintainsOutperform—
29 Oct 2025Goldman SachsMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. KNSA appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

KNSA vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Kiniksa Pharmaceuticals International Plc returned +106.1% against +17.5% for the S&P 500, dividends included.

KNSA vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200Oct 25Jan 26Apr 26Jul 26KNSAS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

KNSA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−3.5%
Analysts raising
1
Analysts cutting
2
Fundamentals

Kiniksa Pharmaceuticals International Plc (KNSA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
77.0×

Cheaper than 9% of US stocks

Price / sales
7.1×

Cheaper than 18% of US stocks

Price / book
9.1×

Cheaper than 10% of US stocks

EV / EBITDA
53.3×

Cheaper than 5% of US stocks

Growth & margins
Revenue growth (YoY)
55.4%

Higher than 87% of US stocks

Earnings growth (YoY)
42.6%

Higher than 72% of US stocks

Gross margin
54.2%

Higher than 67% of US stocks

Operating margin
11.2%

Higher than 66% of US stocks

Net margin
9.6%

Higher than 69% of US stocks

Returns & dividend
Return on equity
14.0%

Higher than 72% of US stocks

Return on assets
8.0%

Higher than 88% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Kiniksa Pharmaceuticals International Plc (KNSA) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Kiniksa Pharmaceuticals International Plc has a market value of $6.0B and an enterprise value of $5.4B.

  • Revenue in the twelve months to 30 June 2026: $840.8M. The latest quarter grew 55.4% year on year.

  • Net income over the same four quarters: $80.7M, a 9.6% net margin.

  • Diluted earnings per share, trailing twelve months: $0.97.

  • Free cash flow in the twelve months to 30 June 2026: $182.8M.

  • Kiniksa Pharmaceuticals International Plc spent $11.1M on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 78.0M.

  • Trailing P/E: 77.0×; forward P/E: 47.2× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Kiniksa Pharmaceuticals International Plc employs 366 people — $2.3M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 14 Sept 2026

Data provided by Twelve Data

Peers

KNSA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
KNSAKiniksa Pharmaceuticals International Plc$6.0B
98
LQDALiquidia Corp.$6.0B
78
HIMSHims & Hers Health, Inc.$6.4B
17
AMRXAmneal Pharmaceuticals, Inc.$5.3B
83
LNTHLantheus Holdings, Inc.$6.5B
88
ALKSAlkermes Plc$7.6B
62
INDVIndivior Pharmaceuticals, Inc.$4.1B
97

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Kiniksa Pharmaceuticals International Plc — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest KNSA news & analysis

Kiniksa Pharmaceuticals to Present at Wells Fargo 21st Annual Healthcare Conference

GlobeNewsWire · 4 Sept 2026neutral

Kiniksa Pharmaceuticals announced that management will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on September 9, 2026 at 8:45 a.m. Eastern Time. The announcement was made in a press release on September 4, 2026.

Why it matters — This conference appearance offers Kiniksa's management an opportunity to discuss its business and strategy with investors and analysts in a widely attended industry forum.

Three Biotech Stocks Stick Out With Their Stellar Charts

Investors Business Daily · 21 Aug 2026positive

An Investors Business Daily article highlights three biotech stocks that gained after their recent earnings reports and have outperformed 97% of stocks over the past 12 months.

Why it matters — This piece draws attention to biotech stocks that have delivered strong chart performance after earnings, providing relevant context for KNSA watchers tracking share-price strength in the sector.

Kiniksa Highlights ARCALYST Growth as KPL-387 Advances Into Phase 3

MarketBeat · 15 Aug 2026positive

Kiniksa Pharmaceuticals said its marketed recurrent pericarditis treatment ARCALYST continues to grow in commercial performance, and the company has started a pivotal Phase 3 study of its follow-on candidate KPL-387.

Why it matters — For KNSA watchers, ARCALYST's sustained growth supports the commercial franchise while the advancement of KPL-387 into Phase 3 signals progress in the pipeline beyond the current product.

Kiniksa Pharmaceuticals to Present at Canaccord Genuity 46th Annual Growth Conference

GlobeNewsWire · 7 Aug 2026neutral

Kiniksa Pharmaceuticals announced that its management will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026, at 9:00 a.m. Eastern Time.

Why it matters — A KNSA watcher would care because the company is scheduled to speak at an investor conference, offering an opportunity for management to provide commentary to the investment community.

KNSA Q2 Earnings Call Backs Higher ARCALYST Sales Outlook

Zacks Investment Research · 3 Aug 2026positive

Kiniksa raised its 2026 sales guidance for ARCALYST following a surge in second-quarter revenue, and it is advancing KPL-387 into Phase 3 development as a potential next growth driver. The company discussed these developments during its Q2 earnings call.

Why it matters — A KNSA watcher would care because the raised ARCALYST outlook points to stronger expected performance, while KPL-387's move into Phase 3 signals progress on a future pipeline driver.

FAQ

Frequently asked questions about KNSA stock

What is the KNSA stock price forecast for 2026-2027?

The 8 Wall Street analysts covering Kiniksa Pharmaceuticals International Plc have a median 12-month price target of $99, with estimates ranging from $87 to $108. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is KNSA stock a buy right now?

Of the 8 analysts covering Kiniksa Pharmaceuticals International Plc, 8 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Kiniksa Pharmaceuticals International Plc 98 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank KNSA?

As at 12 Sept 2026, Kiniksa Pharmaceuticals International Plc ranks 98 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (97 of 100).

Will KNSA stock go up?

No one can know that. What the data says: the median 12-month target from 8 analysts implies +29.1% from the last close, and Ticker Nerd's factor model ranks Kiniksa Pharmaceuticals International Plc 98 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the KNSA stock forecast for 2030?

No analyst covering Kiniksa Pharmaceuticals International Plc publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for KNSA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $87 to $108 over the next 12 months.

How has KNSA stock performed over the past year?

Kiniksa Pharmaceuticals International Plc returned +106.1% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Kiniksa Pharmaceuticals International Plc do?

Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares represents an equity interest in Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company focused on discovering, developing, and commercializing therapies for immune-mediated and inflammatory diseases. The company’s current portfolio centers on products and candidates such as ARCALYST, a marketed interleukin-1 trap used in recurrent pericarditis and related inflammatory conditions, alongside additional clinical-stage programs in immunology and inflammation.

What is the latest news on KNSA?

The most recent item we track (GlobeNewsWire, 4 Sept 2026): "Kiniksa Pharmaceuticals to Present at Wells Fargo 21st Annual Healthcare Conference". Kiniksa Pharmaceuticals announced that management will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on September 9, 2026 at 8:45 a.m. Eastern Time. The announcement was made in a press release on September 4, 2026.

Company

About Kiniksa Pharmaceuticals International Plc.

Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares represents an equity interest in Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company focused on discovering, developing, and commercializing therapies for immune-mediated and inflammatory diseases. The company’s current portfolio centers on products and candidates such as ARCALYST, a marketed interleukin-1 trap used in recurrent pericarditis and related inflammatory conditions, alongside additional clinical-stage programs in immunology and inflammation. Kiniksa serves patients and healthcare providers in the United States, the United Kingdom, and other international markets, with emphasis on specialized treatments for cardiovascular and autoimmune disorders. The company’s role in the healthcare sector is defined by its concentration on targeted biologic medicines that address serious conditions with limited treatment options. Headquartered in London, Kiniksa Pharmaceuticals International, plc operates as a commercial-stage biopharmaceutical business within the global specialty drug market.

CEO Mr. Sanjiv K. Patel · 366 employees · United Kingdom · https://www.kiniksa.com